http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111265662-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111265662-B |
| titleOfInvention | Use of intervention 14-3-3 in the treatment of sepsis |
| abstract | The invention belongs to the technical field of immunotherapy, and discloses a medicament for treating sepsis, which is characterized in that the medicament can inhibit 14-3-3 protein. The invention uses 14-3-3 molecule as target point to treat pyemia for the first time. The targeted 14-3-3 method can realize the immunotherapy of the sepsis, has the advantages of improving the survival rate of the sepsis, relieving inflammation and the like, is suitable for the comprehensive therapy of the sepsis, and is suitable for clinical popularization and application. |
| priorityDate | 2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.